CEFAZOLIN FOR INJECTION 500 MG
CEFAZOLIN (CEFAZOLIN SODIUM) : 500 MG · DIN 02108119 · TEVA CANADA LIMITED
Health Canada status: MARKETED
What is CEFAZOLIN FOR INJECTION?
CEFAZOLIN FOR INJECTION 500 MG contains CEFAZOLIN (CEFAZOLIN SODIUM) : 500 MG. It is listed in the Health Canada Drug Product Database under DIN 02108119, held by TEVA CANADA LIMITED, supplied as POWDER FOR SOLUTION for INTRAMUSCULAR ; INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 13-Apr-2013. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is CEFAZOLIN FOR INJECTION used for?
Treatment of respiratory tract, urinary tract, skin and soft tissue, bone and joint infections, septicemia, endocarditis, and perioperative prophylaxis caused by susceptible organisms.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02108119 |
|---|---|
| Brand name | CEFAZOLIN FOR INJECTION |
| Generic / active ingredient | CEFAZOLIN (CEFAZOLIN SODIUM) : 500 MG |
| Manufacturer | TEVA CANADA LIMITED |
| Strength | 500 MG |
| Dosage form | POWDER FOR SOLUTION |
| Route of administration | INTRAMUSCULAR ; INTRAVENOUS |
| Schedule | Prescription |
| ATC code | J01DB04 CEFAZOLIN |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 13-Apr-2013 |
How is it administered?
Adults: 250 mg to 1 g every 6-12 hours depending on infection. Perioperative prophylaxis: 1 g IV/IM 30-60 mins before surgery. Pediatrics: 25-50 mg/kg/day in 3-4 divided doses.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Reconstituted solutions should be used within 24 hours at room temperature or 72 hours under refrigeration. Pharmacy Bulk Vial contents must be used within 8 hours of puncture.
How is it supplied?
500 mg and 1 g single dose vials; 10 g Pharmacy Bulk Vials.
Contraindications
Hypersensitivity to cefazolin sodium, any ingredient in the formulation, or to the cephalosporin group of antibiotics.
Warnings and precautions
Caution in penicillin-allergic patients (cross-reactivity). Risk of Clostridioides difficile-associated disease, seizures in renal impairment, and severe cutaneous adverse reactions (SCAR).
Is CEFAZOLIN in shortage in Canada?
A Canadian shortage report is on file for this molecule: Active — reported by SANDOZ CANADA INCORPORATED, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code J01DB04 CEFAZOLIN. 15 of 34 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| CEFAZOLIN FOR INJECTION | 1 G | POWDER FOR SOLUTION | HIKMA CANADA LIMITED | MARKETED | DIN 02437112 |
| CEFAZOLIN FOR INJECTION | 1 G | POWDER FOR SOLUTION | TEVA CANADA LIMITED | MARKETED | DIN 02108127 |
| CEFAZOLIN FOR INJECTION | 10 G | POWDER FOR SOLUTION | HIKMA CANADA LIMITED | MARKETED | DIN 02437120 |
| CEFAZOLIN FOR INJECTION | 500 MG | POWDER FOR SOLUTION | HIKMA CANADA LIMITED | MARKETED | DIN 02437104 |
| CEFAZOLIN FOR INJECTION USP | 1 G | POWDER FOR SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02308959 |
| CEFAZOLIN FOR INJECTION USP | 10 G | POWDER FOR SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02308967 |
| CEFAZOLIN FOR INJECTION USP | 500 MG | POWDER FOR SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02308932 |
| CEFAZOLIN FOR INJECTION, USP | 1 G | POWDER FOR SOLUTION | FRESENIUS KABI CANADA LTD | MARKETED | DIN 02237138 |
| CEFAZOLIN FOR INJECTION, USP | 10 G | POWDER FOR SOLUTION | FRESENIUS KABI CANADA LTD | MARKETED | DIN 02237140 |
| CEFAZOLIN FOR INJECTION, USP | 100 G | POWDER FOR SOLUTION | FRESENIUS KABI CANADA LTD | MARKETED | DIN 02401029 |
Who else supplies CEFAZOLIN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. CEFAZOLIN appears in 45 registered pack listings across 7 markets, published on 6 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.